Was going to reply earlier but got busy. The 10 billion dollar...

Was going to reply earlier but got busy. The 10 billion dollar question. Why does Keytruda/Merck need TT/ Qbiotics

Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma among others. It has become the most important drug for Merck, given its contribution to the company’s overall top line, and rocketing growth in sales in the recent years. With sales growth, Keytruda now has a meaningful impact on the company’s earnings and may be a factor in Merck’s future stock price. The growth in sales can be attributed to Keytruda’s superior benefits, and its approvals in several indications, especially lung, which has a large addressable market size. Keytruda has helped Merck post much stronger oncology sales growth, when compared to other pharmaceutical behemoths, such as Pfizer, Roche, and Johnson & Johnson. Etc etc

Would would one of the Worlds largest selling drug need TT. For many reasons, amongst which

Cancer immunology drug, Keytruda, is already one of the best-selling drugs in the world and is well on track to becoming the No. 1 drug by revenue within the next few years. Having already been approved to treat a number of different cancer types, Keytruda is poised to play a crucial role in the company's future sales growth.Over the past couple of weeks, however, Keytruda has been hit by some mixed, if not outright disappointing, clinical results. Let's take a closer look at some of these developments and whether they should worry pharmaceutical investors.

The lung cancer trial setback
The most notable setback so far in 2020 for the drug involved a phase 3 trial treating small-cell lung cancer (SCLC). Merck announced on Jan. 7 that Keytruda failed to extend the lifespan of patients who are diagnosed with the condition, although it helped slow down cancer progression in combination with chemotherapy...

cheers